Celgene Corporation : to Present at Sanford C. Bernstein's 28th Annual Strategic Decisions Conference
05/22/2012| 05:05pm US/Eastern
Recommend:
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Sanford C. Bernstein's 28th Annual Strategic
Decisions Conference on Wednesday, May 30, 2012 at 3:00p.m. EST will be
webcast live and will be available in the investor relations section of
the Company's Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the company's Web site at www.celgene.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Exchange Commission.
In addition to financial information prepared in accordance with U.S.
GAAP, this press release also contains non-GAAP financial measures that
we believe provide investors and management with supplemental
information relating to operating performance and trends that facilitate
comparisons between periods and with respect to projected
information. These non-GAAP measures should be considered in addition
to, but not as a substitute for, the information prepared in accordance
with U.S. GAAP. We typically exclude certain GAAP items that management
does not believe affect our basic operations and that do not meet the
GAAP definition of unusual or non-recurring items. Other
companies may define these measures in different ways. Non-GAAP total
revenue approximates GAAP total revenue for each of the periods
presented. See the attached Reconciliations of GAAP to non-GAAP diluted
earnings per share for explanations of the amounts excluded and included
to arrive at non-GAAP diluted earnings per share amounts for the
three-month and full year periods ended December 31, 2011 and for the
projected amounts for the year ending December 31, 2012.
Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
Executive
Vice President and
Chief Financial Officer
or
Patrick E.
Flanigan III, 908-673-9969
Vice President
Investor Relations
© Business Wire 2012
Recommend :
